Pregnancy and primary pulmonary hypertension : successful outcome with epoprostenol therapy.
Primary pulmonary hypertension (PPH) associated with pregnancy carries a high maternal mortality rate. Short-term epoprostenol infusion has been demonstrated to improve the hemodynamic profile in patients with PPH. We report a successful maternal-fetal outcome with epoprostenol therapy during pregnancy, cesarean section, and postpartum in a patient with PPH. Epoprostenol therapy did not produce any physical or developmental abnormalities in the fetus. A favorable maternal-fetal outcome may occur with a multidisciplinary approach.
Stewart
R
R
Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, University of Texas Medical Branch, Galveston, TX, USA.
Tuazon
D
D
Olson
G
G
Duarte
A G
AG
D000328:Adult; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D011464:Epoprostenol / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy*; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000188:drug therapy*; D011256:Pregnancy Outcome; D016896:Treatment Outcome
D000959:Antihypertensive Agents; D011464:Epoprostenol